As vaccination rates fell off a cliff during the pandemic's first year, GSK and IQVIA are creating a platform to track how well shots are being taken up across the U....

Five days into his tenure as new CEO at Catalent, Alessandro Maselli revealed a restructure of the New Jersey-based contract manufacturer designed to streamline its o...

After a contract manufacturing snafu in December, supply of Novo Nordisk’s GLP-1 med for obesity appears to be back on track in the U.S.—mostly. Novo’s Wegovy ...

While new polls show flatlining concern about the pandemic among Americans, Moderna's COVID-19 vaccine business continues quietly churning in the background. But amid...

With Libtayo now squarely in Regeneron’s hands, the drugmaker is eager to start cranking out combination therapies. But one near-term prospect is expected to suffer a...

Add two more failures to Merck & Co.’s recent string of Keytruda trial readouts. The once seemingly untouchable immuno-oncology agent appears to have hit a snag i...

Secret secrets are no fun, especially when they’re stolen trade secrets with big money on the line. But for two former GSK researchers, their sentences for trade secr...

After years of government standstill on drug prices in the U.S., could the Senate this week pass a "watershed" bill enabling drug price negotiations? It remains to be...

The FDA’s oncology department has lately been tightening its act around accelerated approvals and stressing the importance of patient survival data. Several companies...

Roche is hyping up the early financials coming in for its eye disease therapy Vabysmo as the Swiss major looks to take on the might of Regeneron and Bayer’s major blo...